The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Battle of GLP-1 delivery technologies
Open accessAbstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) belong to an important therapeutic class for treatment of type 2 diabetes. Six GLP-1 RAs, each utilizing a unique drug delivery strategy, are now approved by the Food and Drug Administration (FDA) and additional, novel GLP-1 RAs are still under development, making for a crowded marketplace and fierce competition among the manufacturers of these products. As rapid elimination is a major challenge for clinical application of GLP-1 RAs, various half-life extension strategies have been successfully employed including sequential modification, attachment of fatty-acid to peptide, fusion with human serum albumin, fusion with the fragment crystallizable (Fc) region of a monoclonal antibody, sustained drug delivery systems, and PEGylation. In this review, we discuss the scientific rationale of the various half-life extension strategies used for GLP-1 RA development. By analyzing and comparing different approved GLP-1 RAs and those in development, we focus on assessing how half-life extending strategies impact the pharmacokinetics, pharmacodynamics, safety, patient usability and ultimately, the commercial success of GLP-1 RA products. We also anticipate future GLP-1 RA development trends. Since similar drug delivery strategies are also applied for developing other therapeutic peptides, we expect this case study of GLP-1 RAs will provide generalizable concepts for the rational design of therapeutic peptides products with extended duration of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Global estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients
Sherwani, S. I., Khan, H. A., Ekhzaimy, A., Masood, A., & Sakharkar, M. K. (2016) · Biomarker Insights · doi:10.4137/bmi.s38440 · Cited by 1,381
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Research works printed but not linked: 121
- G. International Diabetes, 2014, Federation Guideline Development, Global guideline for type 2 diabetes, Diabetes Res. Clin. Pract., 104, 1, 10.1016/j.diabres.2012.10.001 · DOI · Paper page
- Marathe, 2017, American Diabetes Association standards of medical care in diabetes 2017, J. Diabetes, 9, 320, 10.1111/1753-0407.12524 · DOI · Paper page
- Holst, 2007, The physiology of glucagon-like peptide 1, Physiol. Rev., 87, 1409, 10.1152/physrev.00034.2006 · DOI · Paper page
- Franek, 2009, The role of glucagon-like peptide 1 in glucose homeostasis and in other aspects of human physiology, Pol. Arch. Med. Wewn., 119, 743, 10.20452/pamw.829 · DOI
- Meloni, 2013, GLP-1 receptor activated insulin secretion from pancreatic beta-cells: mechanism and glucose dependence, Diabetes Obes. Metab., 15, 15, 10.1111/j.1463-1326.2012.01663.x · DOI · Paper page
- Yusta, 2006, GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress, Cell Metab., 4, 391, 10.1016/j.cmet.2006.10.001 · DOI · Paper page
- Wishart, 1998, Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1, Peptides, 19, 1049, 10.1016/S0196-9781(98)00052-7 · DOI
- Henry, 2013, A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes, Clin. Ther., 35, 634, 10.1016/j.clinthera.2013.03.011 · DOI
- Adelhorst, 1994, Structure-activity studies of glucagon-like peptide-1, J. Biol. Chem., 269, 6275, 10.1016/S0021-9258(17)37366-0 · DOI · Paper page
- Sebokova, 2010, Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency, Endocrinology, 151, 2474, 10.1210/en.2009-1459 · DOI
- Goke, 1993, Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells, J. Biol. Chem., 268, 19650, 10.1016/S0021-9258(19)36565-2 · DOI · Paper page
- Thum, 2002, Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4, Exp. Clin. Endocrinol. Diabetes, 110, 113, 10.1055/s-2002-29087 · DOI
- Neidigh, 2001, Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states, Biochemistry, 40, 13188, 10.1021/bi010902s · DOI · Paper page
- Lee, 2018, Replacement of the C-terminal Trp-cage of exendin-4 with a fatty acid improves therapeutic utility, Biochem. Pharmacol., 151, 59, 10.1016/j.bcp.2018.03.004 · DOI
- Simonsen, 2006, Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs, Diabetologia, 49, 706, 10.1007/s00125-005-0128-9 · DOI · Paper page
- Copley, 2006, Investigation of exenatide elimination and its in vivo and in vitro degradation, Curr. Drug Metab., 7, 367, 10.2174/138920006776873490 · DOI
- Thorkildsen, 2003, Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice, J. Pharmacol. Exp. Ther., 307, 490, 10.1124/jpet.103.051987 · DOI
- Kontermann, 2011, Strategies for extended serum half-life of protein therapeutics, Curr. Opin. Biotechnol., 22, 868, 10.1016/j.copbio.2011.06.012 · DOI · Paper page
- Erak, 2018, Peptide chemistry toolbox - transforming natural peptides into peptide therapeutics, Bioorg. Med. Chem., 26, 2759, 10.1016/j.bmc.2018.01.012 · DOI · Paper page
- Frederiksen, 2015, Oligomerization of a glucagon-like peptide 1 analog: bridging experiment and simulations, Biophys. J., 109, 1202, 10.1016/j.bpj.2015.07.051 · DOI
- Steensgaard, 2008, The molecular basis for the delayed absorption of the once-daily human GLP-1 analoge, liraglutide, Diabetes, 57
- Wang, 2015, Transformation of oligomers of lipidated peptide induced by change in pH, Mol. Pharm., 12, 411, 10.1021/mp500519s · DOI
- Spector, 1975, Fatty acid binding to plasma albumin, J. Lipid Res., 16, 165, 10.1016/S0022-2275(20)36723-7 · DOI · Paper page
- Kurtzhals, 1995, Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo, Biochem. J., 312, 725, 10.1042/bj3120725 · DOI · Paper page
- Bertucci, 2002, Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance, Curr. Med. Chem., 9, 1463, 10.2174/0929867023369673 · DOI · Paper page
- Knudsen, 2000, Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration, J. Med. Chem., 43, 1664, 10.1021/jm9909645 · DOI · Paper page
- Watson, 2010, Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide, J. Clin. Pharmacol., 50, 886, 10.1177/0091270009354996 · DOI
- Wang, 2016, The molecular basis for the prolonged blood circulation of lipidated incretin peptides: peptide oligomerization or binding to serum albumin?, J. Control. Release, 241, 25, 10.1016/j.jconrel.2016.08.035 · DOI
- Plum, 2013, In vitro protein binding of liraglutide in human plasma determined by reiterated stepwise equilibrium dialysis, J. Pharm. Sci., 102, 2882, 10.1002/jps.23648 · DOI
- Malm-Erjefalt, 2010, Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase, Drug Metab. Dispos., 38, 1944, 10.1124/dmd.110.034066 · DOI · Paper page
- Jiang, 2011, The pharmacokinetics, pharmacodynamics, and tolerability of liraglutide, a once-daily human GLP-1 analogue, after multiple subcutaneous administration in healthy Chinese male subjects, J. Clin. Pharmacol., 51, 1620, 10.1177/0091270010389468 · DOI
- Lyseng-Williamson, 2017, Coagulation factor IX (recombinant), albumin fusion protein (albutrepenonacog alfa; Idelvion(R)): a review of its use in haemophilia B, Drugs, 77, 97, 10.1007/s40265-016-0679-8 · doi:10.1007/s40265-016-0679-8
- Kim, 2006, Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces, Am. J. Physiol. Gastrointest. Liver Physiol., 290, G352, 10.1152/ajpgi.00286.2005 · DOI
- Sleep, 2013, Albumin as a versatile platform for drug half-life extension, Biochim. Biophys. Acta, 1830, 5526, 10.1016/j.bbagen.2013.04.023 · DOI · Paper page
- Young, 2014, Clinical pharmacology of albiglutide, a GLP-1 receptor agonist, Postgrad. Med., 126, 84, 10.3810/pgm.2014.11.2836 · DOI · Paper page
- Strohl, 2015, Fusion proteins for half-life extension of biologics as a strategy to make biobetters, BioDrugs, 29, 215, 10.1007/s40259-015-0133-6 · DOI · Paper page
- Tzaban, 2009, The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity, J. Cell Biol., 185, 673, 10.1083/jcb.200809122 · DOI · Paper page
- Suzuki, 2010, Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR, J. Immunol., 184, 1968, 10.4049/jimmunol.0903296 · DOI · Paper page
- Kim, 2009, Fc fusion to glucagon-like peptide-1 inhibits degradation by human DPP-IV, increasing its half-life in serum and inducing a potent activity for human GLP-1 receptor activation, BMB Rep., 42, 212, 10.5483/BMBRep.2009.42.4.212 · DOI
- Rath, 2015, Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics, Crit. Rev. Biotechnol., 35, 235, 10.3109/07388551.2013.834293 · DOI · Paper page
- Bruhns, 2009, Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses, Blood, 113, 3716, 10.1182/blood-2008-09-179754 · DOI · Paper page
- Czajkowsky, 2012, Fc-fusion proteins: new developments and future perspectives, EMBO Mol. Med., 4, 1015, 10.1002/emmm.201201379 · DOI · Paper page
- Glaesner, 2010, Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein, Diabetes Metab. Res., 26, 287, 10.1002/dmrr.1080 · DOI · Paper page
- Oh, 2014, Sol-gel transition of nanoparticles/polymer mixtures for sustained delivery of exenatide to treat type 2 diabetes mellitus, Eur. J. Pharm. Biopharm., 88, 664, 10.1016/j.ejpb.2014.08.004 · DOI
- Perez-Ortiz, 2017, Gold nanoparticles as an efficient drug delivery system for GLP-1 peptides, Colloids Surf. B Biointerfaces, 158, 25, 10.1016/j.colsurfb.2017.06.015 · DOI
- Huotari, 2013, Effect of surface chemistry of porous silicon microparticles on glucagon-like peptide-1 (GLP-1) loading, release and biological activity, Int. J. Pharm., 454, 67, 10.1016/j.ijpharm.2013.06.063 · doi:10.1016/j.ijpharm.2013.06.063
- Schwendeman, 2014, Injectable controlled release depots for large molecules, J. Control. Release, 190, 240, 10.1016/j.jconrel.2014.05.057 · DOI · Paper page
- Zhong, 2007, Rescue of SCID murine ischemic hindlimbs with pH-modified rhbFGF/poly(DL-lactic-co-glycolic acid) implants, J. Control. Release, 122, 331, 10.1016/j.jconrel.2007.05.016 · doi:10.1016/j.jconrel.2007.05.016
- Kovalchuk, 2005, Controlled release of goserelin from microporous polyglycolide and polylactide, Macromol. Biosci., 5, 289, 10.1002/mabi.200500033 · doi:10.1002/mabi.200500033
- Okada, 1994, Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers, Pharm. Res., 11, 1143, 10.1023/A:1018936815654 · DOI · Paper page
- Deyoung, 2011, Encapsulation of exenatide in poly-(d,l-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes, Diabetes Technol. Ther., 13, 1145, 10.1089/dia.2011.0050 · DOI · Paper page
- Fineman, 2011, Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing, Clin. Pharmacokinet., 50, 65, 10.2165/11585880-000000000-00000 · DOI
- Henry, 2014, Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes, J. Diabetes Complicat., 28, 393, 10.1016/j.jdiacomp.2013.12.009 · DOI
- Henry, 2013, A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes, Clin. Ther., 35, 634, 10.1016/j.clinthera.2013.03.011 · DOI
- Shu, 2013, Peptide-polymer conjugates: from fundamental science to application, Annu. Rev. Phys. Chem., 64, 631, 10.1146/annurev-physchem-040412-110108 · DOI · Paper page
- Lee, 2005, Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1, Bioconjug. Chem., 16, 377, 10.1021/bc049735+ · DOI
- Schellenberger, 2009, A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner, Nat. Biotechnol., 27, 1186, 10.1038/nbt.1588 · DOI · Paper page
- Podust, 2013, Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer, Protein Eng. Des. Sel., 26, 743, 10.1093/protein/gzt048 · DOI
- Fineman, 2012, GLP-1 based therapies: differential effects on fasting and postprandial glucose, Diabetes Obes. Metab., 14, 675, 10.1111/j.1463-1326.2012.01560.x · DOI
- Calara, 2005, A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4), Clin. Ther., 27, 210, 10.1016/j.clinthera.2005.02.008 · DOI
- Jimenez-Solem, 2010, Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes, Curr. Opin. Mol. Ther., 12, 790
- Hompesch, 2015, Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus, Diabetes Obes. Metab., 17, 82, 10.1111/dom.12398 · DOI
- Nauck, 1997, Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans, Am. J. Phys., 273, E981
- Lorenz, 2013, Effects of lixisenatide once daily on gastric emptying in type 2 diabetes—relationship to postprandial glycemia, Regul. Pept., 185, 1, 10.1016/j.regpep.2013.04.001 · DOI
- Buse, 2010, DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks, Diabetes Care, 33, 1255, 10.2337/dc09-1914 · DOI · Paper page
- Buse, 2013, Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study, Lancet, 381, 117, 10.1016/S0140-6736(12)61267-7 · DOI · Paper page
- Scott, 2013, A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo, Diabetes Obes. Metab., 15, 213, 10.1111/dom.12007 · DOI
- Kayaniyil, 2016, A network meta-analysis comparing exenatide once weekly with other GLP-1 receptor agonists for the treatment of type 2 diabetes mellitus, Diabetes Ther., 7, 27, 10.1007/s13300-016-0155-1 · DOI
- Saunders, 2016, Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study, Diabetes Metab. Syndr. Obes., 9, 217, 10.2147/DMSO.S103972 · DOI
- Barrera, 2011, GLP-1 and energy balance: an integrated model of short-term and long-term control, Nat. Rev. Endocrinol., 7, 507, 10.1038/nrendo.2011.77 · DOI · Paper page
- Baggio, 2004, A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis, Diabetes, 53, 2492, 10.2337/diabetes.53.9.2492 · DOI · Paper page
- Umpierrez, 2014, Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3), Diabetes Care, 37, 2168, 10.2337/dc13-2759 · DOI · Paper page
- Nauck, 2016, Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise, Diabetologia, 59, 266, 10.1007/s00125-015-3795-1 · DOI
- Russell-Jones, 2012, Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study, Diabetes Care, 35, 252, 10.2337/dc11-1107 · DOI · Paper page
- Marre, 2009, Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU), Diabet. Med., 26, 268, 10.1111/j.1464-5491.2009.02666.x · DOI · Paper page
- Trujillo, 2014, GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents, Pharmacotherapy, 34, 1174, 10.1002/phar.1507 · DOI
- Gentilella, 2009, Exenatide: a review from pharmacology to clinical practice, Diabetes Obes. Metab., 11, 544, 10.1111/j.1463-1326.2008.01018.x · DOI
- Pinget, 2013, Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P), Diabetes Obes. Metab., 15, 1000, 10.1111/dom.12121 · DOI
- Rosenstock, 2016, I. Getgoal Duo-2 trial, prandial options to advance basal insulin glargine therapy: testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: the GetGoal Duo-2 trial, Diabetes Care, 39, 1318, 10.2337/dc16-0014 · DOI
- Seino, 2012, Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia), Diabetes Obes. Metab., 14, 910, 10.1111/j.1463-1326.2012.01618.x · DOI · Paper page
- Pan, 2014, Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia), Diabetes Metab. Res. Rev., 30, 726, 10.1002/dmrr.2541 · DOI
- Ahren, 2014, HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin, Diabetes Care, 37, 2141, 10.2337/dc14-0024 · DOI · Paper page
- Home, 2015, Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5, Diabetes Obes. Metab., 17, 179, 10.1111/dom.12414 · DOI
- Reusch, 2014, Diabetes Obes. Metab., 16, 1257, 10.1111/dom.12382 · DOI
- Weissman, 2014, HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea, Diabetologia, 57, 2475, 10.1007/s00125-014-3360-3 · DOI
- Blonde, 2015, Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study, Lancet, 385, 2057, 10.1016/S0140-6736(15)60936-9 · DOI · Paper page
- Nauck, 2007, A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study, Diabetologia, 50, 259, 10.1007/s00125-006-0510-2 · DOI · Paper page
- Fineman, 2012, Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment, Diabetes Obes. Metab., 14, 546, 10.1111/j.1463-1326.2012.01561.x · DOI
- Jones, 2015, Injection-site nodules associated with the use of exenatide extended-release reported to the U.S. Food and Drug Administration adverse event reporting system, Diabetes Spectr., 28, 283, 10.2337/diaspect.28.4.283 · DOI
- Blonde, 2009, The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies, Diabetes Obes. Metab., 11, 26, 10.1111/j.1463-1326.2009.01075.x · DOI · Paper page
- Leiter, 2014, Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study, Diabetes Care, 37, 2723, 10.2337/dc13-2855 · DOI
- Rosenstock, 2014, Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro, Diabetes Care, 37, 2317, 10.2337/dc14-0001 · DOI · Paper page
- Elashoff, 2011, Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies, Gastroenterology, 141, 150, 10.1053/j.gastro.2011.02.018 · DOI · Paper page
- Balena, 2013, Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature, Diabetes Obes. Metab., 15, 485, 10.1111/dom.12025 · DOI
- 2017, Diabetes Care, 40, S4, 10.2337/dc17-S003 · DOI · Paper page
- Ross, 2013, Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes, Am. J. Med., 126, S38, 10.1016/j.amjmed.2013.06.012 · DOI
- Fu, 2009, Impact of fear of insulin or fear of injection on treatment outcomes of patients with diabetes, Curr. Med. Res. Opin., 25, 1413, 10.1185/03007990902905724 · DOI
- Pfutzner, 2011, Evaluation of dexterity in insulin-treated patients with type 1 and type 2 diabetes mellitus, J. Diabetes Sci. Technol., 5, 158, 10.1177/193229681100500122 · DOI
- Baekdal, 2018, Pharmacokinetics, safety, and tolerability of oral Semaglutide in subjects with hepatic impairment, J. Clin. Pharmacol., 1
- Malkov, 2005, Oral delivery of insulin with the eligen technology: mechanistic studies, Curr. Drug Deliv., 2, 191, 10.2174/1567201053586001 · DOI
- Holst, 2017, Semaglutide seems to be more effective the other GLP-1Ras, Ann. Transl. Med., 5, 505, 10.21037/atm.2017.11.10 · DOI
- Davies, 2017, Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial, JAMA, 318, 1460, 10.1001/jama.2017.14752 · DOI · Paper page
- Kapitza, 2015, Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel, J. Clin. Pharmacol., 55, 497, 10.1002/jcph.443 · DOI · Paper page
- Leone-Bay, 2009, Evaluation of novel particles as an inhalation system for GLP-1, Diabetes Obes. Metab., 11, 1050, 10.1111/j.1463-1326.2009.01096.x · DOI
- Marino, 2010, Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): proof-of-concept studies in healthy normal volunteers and in patients with type 2 diabetes, Clin. Pharmacol. Ther., 88, 243, 10.1038/clpt.2010.85 · DOI
- Shahzad, 2015, Breaching the skin barrier through temperature modulations, J. Control. Release, 202, 1, 10.1016/j.jconrel.2015.01.019 · doi:10.1016/j.jconrel.2015.01.019
- Cefalu, 2001, Inhaled human insulin treatment in patients with type 2 diabetes mellitus, Ann. Intern. Med., 134, 203, 10.7326/0003-4819-134-3-200102060-00011 · DOI · Paper page
- Black, 2007, The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation, Health Technol. Assess., 11, 1, 10.3310/hta11330 · DOI
- Smart, 2014, Oral peptide and protein delivery: intestinal obstacles and commercial prospects, Expert Opin. Drug Deliv., 11, 1323, 10.1517/17425247.2014.917077 · DOI
- Heinemann, 2009, Oral insulin and buccal insulin: a critical reappraisal, J. Diabetes Sci. Technol., 3, 568, 10.1177/193229680900300323 · DOI
- Fonte, 2013, Oral insulin delivery: how far are we?, J. Diabetes Sci. Technol., 7, 520, 10.1177/193229681300700228 · DOI · Paper page
- Zarogoulidis, 2011, Inhaled insulin: too soon to be forgotten?, J. Aerosol Med. Pulm. Drug Deliv., 24, 213, 10.1089/jamp.2011.0876 · doi:10.1089/jamp.2011.0876
- Mitri, 2009, Inhaled insulin—what went wrong, Nat. Clin. Pract. Endocrinol. Metab., 5, 24, 10.1038/ncpendmet1007 · DOI
- Patel, 2013, Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice, Can. J. Physiol. Pharmacol., 91, 1009, 10.1139/cjpp-2013-0189 · DOI
- Pocai, 2009, Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice, Diabetes, 58, 2258, 10.2337/db09-0278 · DOI · Paper page
- Deryabina, 2015, Pharmacokinetics and pharmacodynamics of GLP-1-GIP receptor dual agonist peptides: from once-daily to once-weekly, Diabetes, 64
- Fosgerau, 2013, The novel GLP-1-gastrin dual agonist, ZP3022, increases beta-cell mass and prevents diabetes in db/db mice, Diabetes Obes. Metab., 15, 62, 10.1111/j.1463-1326.2012.01676.x · DOI
- Soni, 2016, Peptide-based GLP-1/glucagon co-agonists: a double-edged sword to combat diabesity, Med. Hypotheses, 95, 5, 10.1016/j.mehy.2016.08.005 · DOI
- Henderson, 2016, Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates, Diabetes Obes. Metab., 18, 1176, 10.1111/dom.12735 · DOI · Paper page
- Chakradhar, 2016, All in one: researchers create combination drugs for diabetes and obesity, Nat. Med., 22, 694, 10.1038/nm0716-694 · DOI
- Fosgerau, 2013, The novel GLP-1-gastrin dual agonist, ZP3022, increases ss-cell mass and prevents diabetes in db/db mice, Diabetes Obes. Metab., 15, 62, 10.1111/j.1463-1326.2012.01676.x · DOI
Cited by
Type II diabetes mellitus: a review on recent drug based therapeutics.
Padhi, S., Nayak, A. K., & Behera, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110708 · Cited by 726
G protein-coupled receptors: structure- and function-based drug discovery
Yang, D., Zhou, Q., Labroska, V., Qin, S., Darbalaei, S., Wu, Y., Yuliantie, E., Xie, L., Tao, H., Cheng, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00435-w · Cited by 632
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 492
Cyclic peptide drugs approved in the last two decades (2001–2021)
Zhang, H., & Chen, S. (2022) · RSC Chemical Biology · doi:10.1039/d1cb00154j · Cited by 319
Gao, Y., Peng, K., & Mitragotri, S. (2021) · Advanced Materials · doi:10.1002/adma.202006362 · Cited by 295
Metadata
- Authors
- Yu, M., Benjamin, M. M., Srinivasan, S., Morin, E. E., Shishatskaya, E. I., Schwendeman, S. P., & Schwendeman, A.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 130
- Pages
- 113-130
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2883953772
- Cited by
- 180
- References
- 51
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- NIH (HL134569, T32 GM008353, T32 HL125242)
- Amneal Pharmaceuticals (N023714-00)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Battle of GLP-1 delivery technologies. https://app.cochat.ai/papers/10.1016/j.addr.2018.07.009
- The paper
- Yu, M., Benjamin, M. M., Srinivasan, S., Morin, E. E., Shishatskaya, E. I., Schwendeman, S. P., & Schwendeman, A. (2018). Battle of GLP-1 delivery technologies. Advanced Drug Delivery Reviews. https://doi.org/10.1016/j.addr.2018.07.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.